1. Home
  2. BDJ vs MESO Comparison

BDJ vs MESO Comparison

Compare BDJ & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Enhanced Equity Dividend Trust

BDJ

Blackrock Enhanced Equity Dividend Trust

HOLD

Current Price

$9.73

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.73

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDJ
MESO
Founded
2005
2004
Country
United States
Australia
Employees
N/A
81
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BDJ
MESO
Price
$9.73
$16.73
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
581.4K
215.0K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
8.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$629.74
Revenue Next Year
N/A
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.42
$11.05
52 Week High
$9.76
$21.50

Technical Indicators

Market Signals
Indicator
BDJ
MESO
Relative Strength Index (RSI) 68.88 68.30
Support Level $9.05 $13.82
Resistance Level N/A $17.33
Average True Range (ATR) 0.09 0.45
MACD 0.01 0.28
Stochastic Oscillator 100.00 98.40

Price Performance

Historical Comparison
BDJ
MESO

About BDJ Blackrock Enhanced Equity Dividend Trust

BlackRock Enhanced Equity Dividend Trust is a closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option to enhance distributions to its shareholders.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: